Dawn Christine Maroney Sells 100,000 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) President Dawn Christine Maroney sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $20.03, for a total value of $2,003,000.00. Following the sale, the president owned 1,285,167 shares of the company’s stock, valued at approximately $25,741,895.01. This trade represents a 7.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Dawn Christine Maroney also recently made the following trade(s):

• On Tuesday, January 6th, Dawn Christine Maroney sold 228,152 shares of Alignment Healthcare stock. The shares were sold at an average price of $21.33, for a total value of $4,866,482.16.
• On Monday, December 29th, Dawn Christine Maroney sold 282,070 shares of Alignment Healthcare stock. The stock was sold at an average price of $18.74, for a total value of $5,285,991.80.
• On Monday, December 15th, Dawn Christine Maroney sold 113,319 shares of Alignment Healthcare stock. The shares were sold at an average price of $20.01, for a total value of $2,267,513.19.
• On Friday, December 12th, Dawn Christine Maroney sold 16,681 shares of Alignment Healthcare stock. The shares were sold at an average price of $20.02, for a total value of $333,953.62.

Alignment Healthcare Trading Down 1.7%

Shares of ALHC opened at $20.93 on Thursday. Alignment Healthcare, Inc. has a 52-week low of $11.48 and a 52-week high of $21.65. The stock has a market cap of $4.19 billion, a PE ratio of -174.42, a price-to-earnings-growth ratio of 6.12 and a beta of 1.16. The firm’s fifty day moving average is $18.55 and its two-hundred day moving average is $16.46. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. The firm had revenue of $993.70 million for the quarter, compared to the consensus estimate of $980.90 million. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The company’s revenue for the quarter was up 43.5% on a year-over-year basis. During the same period last year, the firm posted ($0.14) earnings per share. Research analysts forecast that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Alignment Healthcare News Roundup

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent quarterly results showed revenue strength and an EPS beat (Qtr revenue ≈ $993.7M, +43.5% YoY; EPS $0.02 vs. consensus -$0.01), which supports growth expectations and helps explain upside interest from investors. Read More.
• Neutral Sentiment: Analyst coverage is active — some firms have raised price targets (consensus ~$21.25) while others remain neutral; Benzinga’s analyst roundup could amplify moves if any major upgrades or target changes are published. Read More.
• Negative Sentiment: Large insider sales were disclosed this week, including significant dispositions by President Dawn Maroney (100,000 shares sold ~Jan 2 and a separate filing showing 228,152 shares sold) and other executives (Christopher Joyce, Hyong Kim). Investors often interpret material executive selling near highs as profit-taking or reduced insider conviction, which can pressure the stock. Read More. • Read More.
• Negative Sentiment: A recent valuation-focused piece raises the question of whether current valuations already price in expected growth, signalling potential overpaying risk for new buyers if execution slows or multiples compress. That stokes caution even with solid top-line growth. Read More.

Institutional Investors Weigh In On Alignment Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC increased its position in shares of Alignment Healthcare by 6.3% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock worth $196,000 after purchasing an additional 665 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Alignment Healthcare by 2.3% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,752 shares of the company’s stock worth $659,000 after buying an additional 844 shares during the period. Tidal Investments LLC increased its position in shares of Alignment Healthcare by 4.9% during the second quarter. Tidal Investments LLC now owns 18,094 shares of the company’s stock valued at $253,000 after acquiring an additional 852 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Alignment Healthcare by 83.8% in the 4th quarter. GAMMA Investing LLC now owns 2,165 shares of the company’s stock valued at $43,000 after acquiring an additional 987 shares during the period. Finally, Jefferies Financial Group Inc. lifted its holdings in shares of Alignment Healthcare by 4.3% in the 3rd quarter. Jefferies Financial Group Inc. now owns 24,359 shares of the company’s stock worth $425,000 after acquiring an additional 1,014 shares during the last quarter. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on ALHC. JPMorgan Chase & Co. increased their price target on Alignment Healthcare from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Piper Sandler upped their target price on Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. UBS Group boosted their price target on shares of Alignment Healthcare from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alignment Healthcare in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.25.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.